Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median ...

Patients with oligometastatic lung cancer may live longer with surgery, but experts stress the need for multidisciplinary ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the ...

Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the ...

Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the ...

According to the company, the niraparib combination demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) and time to ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ...

A long-term follow-up of early total therapy trials suggests that up to one-third of patients with newly diagnosed multiple ...

Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations.

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung ...